Cited by 146Systemic Lupus Erythematosus ResearchNeuroinflammation and Neurodegeneration MechanismsAutoimmune Neurological Disorders and Treatments

Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors

Open access
Nestor, Jacquelyn, Arinuma, Yoshiyuki, Huerta, Tomás S., Kowal, Czeslawa, Nasiri, Elham, Kello, Nina, Fujieda, Yuichiro, Bialas, Alison +6 more·2018·Journal of Experimental Medicine

Abstract

Cognitive impairment occurs in 40-90% of patients with systemic lupus erythematosus (SLE), which is characterized by autoantibodies to nuclear antigens, especially DNA. We discovered that a subset of anti-DNA antibodies, termed DNRAbs, cross reacts with the N-methyl-d-aspartate receptor (NMDAR) and enhances NMDAR signaling. In patients, DNRAb presence associates with spatial memory impairment. In a mouse model, DNRAb-mediated brain pathology proceeds through an acute phase of excitotoxic neuron loss, followed by persistent alteration in neuronal integrity and spatial memory impairment. The latter pathology becomes evident only after DNRAbs are no longer detectable in the brain. Here we investigate the mechanism of long-term neuronal dysfunction mediated by transient exposure to antibody. We show that activated microglia and C1q are critical mediators of neuronal damage. We further show that centrally acting inhibitors of angiotensin-converting enzyme (ACE) can prevent microglial activation and preserve neuronal function and cognitive performance. Thus, ACE inhibition represents a strong candidate for clinical trials aimed at mitigating cognitive dysfunction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20180776

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mechanistic dissections of the CNS manifestations of lupus have demonstrated a role for type I interferon signaling and autoantibodies in promoting inappropriate complement- and microglia-mediated engulfment of synapses.

    “Strikingly, mechanistic dissections of the CNS manifestations of the autoimmune disorder, lupus, have demonstrated a role for type I interferon signaling and autoantibodies in promoting inappropriate complement- and microglia-mediated engulfment of synapses (5, 106).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nestor, J., Arinuma, Y., Huerta, T. S., Kowal, C., Nasiri, E., Kello, N., Fujieda, Y., Bialas, A., Hammond, T., Sriram, U., Stevens, B., Huerta, P. T., Volpe, B. T., & Diamond, B.
Affiliations
  • Feinstein Institute for Medical Research (US)
  • Kitasato University (JP)
  • Center for Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY 1
  • Hokkaido University (JP)
  • Boston Children's Hospital (US)
  • Temple University (US)
Corresponding author
Diamond, Betty
Venue
Journal of Experimental Medicine
Published
2018-09-05
Volume
215
Issue
10
Pages
2554-2566
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2889875251
Cited by
146
References
61
Citations by year
2026: 6 · 2025: 15 · 2024: 20 · 2023: 12 · 2022: 28 · 2021: 20 · 2020: 30 · 2019: 12 · 2018: 3
FWCI
13.88
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (NIH P01AI073693, NIH R03-AR065157)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Neurology › Autoimmune Neurological Disorders and Treatments
Keywords
systemic lupus erythematosus, anti-DNA antibodies, NMDA receptor, excitotoxicity, microglial activation, C1q, spatial memory impairment, cognitive impairment, ACE inhibitors, neuronal injury, autoantibodies
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Animals, Antibodies, Antinuclear, Autoantibodies, Brain, Female, Lupus Erythematosus, Systemic, Memory Disorders, Mice, Inbred BALB C, Neurons, Receptors, N-Methyl-D-Aspartate, Microglia, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review